ArticleEmergency radiology2025
Acquired uterine arteriovenous malformation: efficacy of the use of absorbable haemostatic gelatin in uterine artery embolisation.
Article in Emergency radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and complications of absorbable haemostatic gelatin uterine artery embolisation for symptomatic acquired uterine arterio-venous malformation (UAVM).
methodsAll the adult female patients who had acute urogenital bleeding due to UAVM confirmed on ultrasound and received uterine artery embolisation (UAE) for UAVM in a tertiary institution between January 2000 and October 2024 were included. Patients who had UAE for other causes were excluded. Causes of UAVM, embolic agents used, procedural success, recurrent genital bleeding, and complications like pulmonary embolism and groin bleeding were recorded.
resultsSeven female patients (mean age: 34 years) with 8 UAE procedures were included, with three postpartum and four after miscarriages. The mean length of follow-up after UAE was 50 months. Absorbable gelatin was used in six patients, and polyvinyl alcohol (PVA) particles were used in one patient. 5/6 patients (83.3%) had successful UAE with absorbable haemostatic gelatin. There were no procedure-related complications, including pulmonary embolism and uterine infarcts. Only one patient required a repeated UAE 33 days later for recurrent vaginal bleeding, which required sodium tetradecyl sulphate injection and microcoils during embolisation.
conclusionAcquired UAVM is very rare but life-threatening. Absorbable haemostatic gelatin, a temporary embolic agent, appears safe and effective in treating UAVM with uterine preservation. It eliminates the potential risk of uterine infarction that might occur with permanent embolic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.